Key result
Dapagliflozin administered at 1.5 mg/kg/day did not significantly improve survival, pulmonary vascular remodeling, or right ventricular function in rat models of pulmonary arterial hypertension and right ventricular pressure overload.
Why the study?
Although SGLT2 inhibitors provide cardiovascular and heart failure benefits, their efficacy in pulmonary arterial hypertension and right ventricular dysfunction remains unknown.
Does dapagliflozin improve survival, pulmonary vascular remodeling, and right ventricular function in rat models of pulmonary arterial hypertension and right ventricular dysfunction?
Does dapagliflozin improve survival, pulmonary vascular remodeling, and right ventricular function in rat models of pulmonary arterial hypertension and right ventricular dysfunction?
Dapagliflozin did not demonstrate protective effects on pulmonary vascular or right ventricular remodeling in rat models of PAH and RV dysfunction, suggesting caution for its use in these conditions.
Dapagliflozin shows no benefit in rat PAH models; leaves open translation to human disease.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a novel class of hypoglycemic drugs, show excellent cardiovascular benefits, and have further improved heart failure outcomes, significantly reducing cardiovascular and all-cause mortality irrespective of diabetes status. However, the efficacy of SGLT2 inhibitors in pulmonary arterial hypertension (PAH) and right ventricular (RV) dysfunction remains unknown. This study aimed to evaluate the effects of dapagliflozin in rats with PAH and RV dysfunction. PAH was induced in rats by monocrotaline (MCT) subcutaneous injection (60 mg/kg). Isolated RV dysfunction was induced in another group of rats by pulmonary trunk banding (PTB). Dapagliflozin (1.5 mg/kg) was administered daily via oral gavage one day (prevention groups) or two weeks (reversal groups) after modeling. Echocardiography and hemodynamic assessments were used to observe pulmonary vascular resistance and RV function. Histological staining was used to observe pulmonary vascular and RV remodeling. As compared with MCT group, dapagliflozin treatment did not significantly improve the survival of rats. Pulmonary arterial media wall thickness in MCT group was significantly increased, but dapagliflozin did not significantly improved vascular remodeling both in the prevention group and reversal group. In MCT group, RV hypertrophy index, RV area, the fibrosis of RV increased significantly, and RV function decreased significantly. Consistently, dapagliflozin did not show protective effect on the RV remodeling and function. In the PTB model, we also did not find the direct effect of dapagliflozin on the RV. This is a negative therapeutic experiment, suggesting human trials with dapagliflozin for PAH or RV failure should be cautious.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied Pulmonary Arterial Hypertension and Right Ventricular Dysfunction (n=87). Dapagliflozin vs. Vehicle (sterile water) was evaluated on Survival, pulmonary vascular remodeling, and right ventricular function. Dapagliflozin administered at 1.5 mg/kg/day did not significantly improve survival, pulmonary vascular remodeling, or right ventricular function in rat models of pulmonary arterial hypertension and right ventricular pressure overload.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: